Inflammation at diagnosis and cognitive impairment two years later in breast cancer patients from the Canto-Cog study
Mylène Duivon(Inserm), Florence Joly(Inserm), Caroline Pradon(Institut Gustave Roussy), Antonio Di Meglio(Inserm), Justine Lequesne(Centre Henri Becquerel), Marie Lange(Inserm), Christelle Lévy(Centre François Baclesse), Sophie Broutin(Université Paris-Saclay), Olivier Rigal(Centre Henri Becquerel), Inês Vaz-Luís(Institut Gustave Roussy), Anne-Laure Martin(UniCancer Group), Sibille Everhard(Assistance Publique – Hôpitaux de Paris), Florence Lerebours(Institut Curie), Chayma Bousrih(Institut Gustave Roussy)
Cited by 15
Related Papers
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> Mutations
|Cancer Discovery|2017|457
BRAF Inhibition in <i>BRAF</i> <sup>V600</sup> -Mutant Gliomas: Results From the VE-BASKET Study
|Journal of Clinical Oncology|2018|330
An international prospective study of the EORTC cancer in-patient satisfaction with care measure (EORTC IN-PATSAT32)
|European Journal of Cancer|2005|241